- Home
- MYGN vs BBUC Comparison
MYGN vs BBUC Comparison
Compare MYGN & BBUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- BBUC
- Stock Information
- Founded
- MYGN 1991
- BBUC 2022
- Country
- MYGN United States
- BBUC United States
- Employees
- MYGN N/A
- BBUC N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BBUC
- Sector
- MYGN Health Care
- BBUC
- Exchange
- MYGN Nasdaq
- BBUC Nasdaq
- Market Cap
- MYGN 744.7M
- BBUC 1.7B
- IPO Year
- MYGN 1995
- BBUC N/A
- Fundamental
- Price
- MYGN $5.52
- BBUC $31.31
- Analyst Decision
- MYGN Hold
- BBUC
- Analyst Count
- MYGN 15
- BBUC 0
- Target Price
- MYGN $15.14
- BBUC N/A
- AVG Volume (30 Days)
- MYGN 1.8M
- BBUC 104.5K
- Earning Date
- MYGN 08-05-2025
- BBUC 01-01-0001
- Dividend Yield
- MYGN N/A
- BBUC 0.80%
- EPS Growth
- MYGN N/A
- BBUC N/A
- EPS
- MYGN N/A
- BBUC N/A
- Revenue
- MYGN $831,300,000.00
- BBUC $8,309,000,000.00
- Revenue This Year
- MYGN N/A
- BBUC N/A
- Revenue Next Year
- MYGN $6.68
- BBUC N/A
- P/E Ratio
- MYGN N/A
- BBUC N/A
- Revenue Growth
- MYGN 7.38
- BBUC 8.15
- 52 Week Low
- MYGN $3.81
- BBUC $19.65
- 52 Week High
- MYGN $29.30
- BBUC $31.87
- Technical
- Relative Strength Index (RSI)
- MYGN 55.99
- BBUC 65.74
- Support Level
- MYGN $4.90
- BBUC $29.86
- Resistance Level
- MYGN $5.50
- BBUC $31.44
- Average True Range (ATR)
- MYGN 0.25
- BBUC 0.73
- MACD
- MYGN 0.09
- BBUC 0.19
- Stochastic Oscillator
- MYGN 84.46
- BBUC 93.47
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.